NCT06118008 - A Study of HS-20094 in T2DM Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

HS-20094 5mg

Administrated by subcutaneous injection

DRUG

HS-20094 10mg

Administrated by subcutaneous injection

DRUG

HS-20094 15mg

Administrated by subcutaneous injection

DRUG

HS-20094 20mg

Administrated by subcutaneous injection

Trial Locations (1)

Peking University First Hospital, Beijing